Back to search results

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Prostate Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Dana-Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Principal Investigator (Himisha Beltran, MD)

  • New York Presbyterian/Brooklyn Methodist Hospital, Brooklyn, New York, United States

    Contact: Principal Investigator (Peter Gregos, MD)

  • New York Presbyterian/Weill Cornell Medical Center, New York, New York, United States

    Contact: Study coordinator (GUOnc Research Team) · guonc@med.cornell.edu
    Contact: Study coordinator (Sarah Yuan) · say7008@med.cornell.edu · 646-962-6040
    Contact: Principal Investigator (Scott Tagawa, MD, MS)

  • Columbia University Irving Cancer Center, New York, New York, United States

    Contact: Study coordinator (Cancer Clinical Trials Research Team) · cancerclinicaltrials@cumc.columbia.edu · 212-342-5162
    Contact: Principal Investigator (Mark Stein, MD)
Study leads

  • Scott Tagawa, MD, MS

    Principal Investigator

    Weill Medical College of Cornell University

View source on ClinicalTrials.gov(opens in a new tab)